Project Number ADDF-33 Agency/Funding Organization Alzheimer's Drug Discovery Foundation Funding Year 2021 View Full Project Details for Evaluating the effects of GLP-1 analog, oral semaglutide, as a treatment for sporadic behavioral variant frontotemporal dementia (bvFTD) Research Categorization Primary Disease / Condition Frontotemporal Dementia CADRO Category C. Translational Research and Clinical Interventions 8. Late-stage Clinical Drug Development (Phase II/III and III Clinical Trials) j. Metabolism and Bioenergetics Researcher and Organization Principal Investigator Edison, Paul Principal Investigator First Name Paul Principal Investigator Last Name Edison Awardee Organization Imperial College of London Awardee State England Contact PI Country United Kingdom Project Detail Funding Opportunity Announcement ADDF-Clinical Trial Program FY Overall Cost $2,000,000 Funding Organization Agency/Funding Organization Alzheimer's Drug Discovery Foundation Funding Organization Country United States Program Official ADDF Grants Management